MLMichael S. Lustgarten

Michael S. Lustgarten

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Michael S. Lustgarten has a total of 45 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Metabolomic Signatures of Extreme Old Age: Findings from the New England Centenarian Study

    by Stefano Monti, Michael S. Lustgarten, Ziwei Huang, Zeyuan Song, Dylan Ellis, Qu Tian, Luigi Ferrucci, Noa Rappaport, Stacy L. Andersen, Thomas P. Perls, et al.

    The New England Centenarian Study (NECS) provides a unique resource for the study of extreme human longevity (EL). To gain insight into biological pathways related to EL, chronological age and survival, we used an untargeted serum metabolomic approach (> 1,400 metabolites) in 213 NECS participants, followed by integration of our findings with metabolomic data from four additional studies. Compared to their offspring and matched controls, EL individuals exhibited a distinct metabolic profile characterized by higher levels of primary and secondary bile acids – most notably chenodeoxycholic acid (CDCA) and lithocholic acid (LCA) – higher levels of biliverdin and bilirubin, and stable levels of selected steroids. Notably, elevated levels of both bile acids and steroids were associated with lower mortality. Several metabolites associated with age and survival were inversely associated with metabolite ratios related to NAD+ production and/or levels (tryptophan/kynurenine, cortisone/cortisol), gut bacterial metabolism (ergothioneine/ trimethylamine N-oxide, aspartate/quinolinate), and oxidative stress (methionine/methionine sulfoxide), implicating these pathways in aging and/or longevity. We further developed a metabolomic clock predictive of biological age, with age deviations significantly associated with mortality risk. Key metabolites predictive of biological aging, such as taurine and citrate, were not captured by traditional age analyses, pointing to their potential role as biomarkers for healthy aging. These results highlight metabolic pathways that may be targeted to promote metabolic resilience and healthy aging.


  • Open Access

    APOE Genotype and Biological Age Impact Inter-Omic Associations Related to Bioenergetics

    by Dylan Ellis, Kengo Watanabe, Tomasz Wilmanski, Michael S. Lustgarten, Andres V Ardisson Korat, Gwênlyn Glusman, Jennifer J. Hadlock, Oliver Fiehn, Paola Sebastiani, Nathan D. Price, et al.

    Apolipoprotein E ( APOE ) modifies human aging; specifically, the ε2 and ε4 alleles are among the strongest genetic predictors of longevity and Alzheimer’s disease (AD) risk, respectively. However, detailed mechanisms for their influence on aging remain unclear. Herein, we analyzed inter-omic, context-dependent association patterns across APOE genotypes, sex, and health axes in 2,229 community-dwelling individuals to test APOE genotypes for variation in metabolites and metabolite-associations tied to a previously-validated metric of biological aging (BA) based on blood biomarkers. Our analysis, supported by validation in an independent cohort, identified top APOE -associated plasma metabolites as diacylglycerols, which were increased in ε2-carriers and trended higher in ε4-carriers compared to ε3-homozygotes, despite the known opposing aging effects of the allele variants. ‘Omics association patterns of ε2-carriers and increased biological age were also counter-intuitively similar, displaying increased associations between insulin resistance markers and energy-generating pathway metabolites. These results provide an atlas of APOE -related ‘omic associations and support the involvement of bioenergetic pathways in mediating the impact of APOE on aging.


  • Open Access

    Impact of a Whole-Food, High-Soluble Fiber Diet on the Gut–Muscle Axis in Aged Mice

    by Roger A. Fielding, Michael S. Lustgarten

    Previous studies have identified a role for the gut microbiome and its metabolic products, short-chain fatty acids (SCFAs), in the maintenance of muscle mass and physical function (i.e., the gut–muscle axis), but interventions aimed at positively impacting the gut–muscle axis during aging are sparse. Gut bacteria ferment soluble fiber into SCFAs, and accordingly, to evaluate the impact of a high-soluble-fiber diet (HSFD) on the gut–muscle axis, we fed a whole-food, 3×-higher-soluble fiber-containing diet (relative to standard chow) to aged (98 weeks) C57BL/6J mice for 10 weeks. The HSFD significantly altered gut bacterial community structure and composition, but plasma SCFAs were not different, and a positive impact on muscle-related measures (when normalized to body weight) was not identified. However, when evaluating sex differences between dietary groups, female (but not male) HSFD-fed mice had significant increases for SCFAs, the quadriceps/body weight (BW) ratio, and treadmill work performance (distance run × BW), which suggests that an HSFD can positively impact the gut–muscle axis. In contrast, consistent effects in both male and female HSFD-fed mice included weight and fat loss, which suggests a positive role for an HSFD on the gut–adipose axis in aged mice.


  • Model organism life extending therapeutics modulate diverse nodes in the drug-gene-microbe tripartite human longevity interactome

    by Rahagir Salekeen, Michael S. Lustgarten, Umama Khan, Kazi Mohammed Didarul Islam

    Advances in antiaging drug/lead discovery in animal models constitute a large body of literature on novel senotherapeutics and geroprotectives. However, with little direct evidence or mechanism of action in humans—these drugs are utilized as nutraceuticals or repurposed supplements without proper testing directions, appropriate biomarkers, or consistent in-vivo models. In this study, we take previously identified drug candidates that have significant evidence of prolonging lifespan and promoting healthy aging in model organisms, and simulate them in human metabolic interactome networks. Screening for drug-likeness, toxicity, and KEGG network correlation scores, we generated a library of 285 safe and bioavailable compounds. We interrogated this library to present computational modeling-derived estimations of a tripartite interaction map of animal geroprotective compounds in the human molecular interactome extracted from longevity, senescence, and dietary restriction-associated genes. Our findings reflect previous studies in aging-associated metabolic disorders, and predict 25 best-connected drug interactors including Resveratrol, EGCG, Metformin, Trichostatin A, Caffeic Acid and Quercetin as direct modulators of lifespan and healthspan-associated pathways. We further clustered these compounds and the functionally enriched subnetworks therewith to identify longevity-exclusive, senescence-exclusive, pseudo-omniregulators and omniregulators within the set of interactome hub genes. Additionally, serum markers for drug-interactions, and interactions with potentially geroprotective gut microbial species distinguish the current study and present a holistic depiction of optimum gut microbial alteration by candidate drugs. These findings provide a systems level model of animal life-extending therapeutics in human systems, and act as precursors for expediting the ongoing global effort to find effective antiaging pharmacological interventions. Communicated by Ramaswamy H. Sarma


  • In silico insights into potential gut microbial modulation of NAD+ metabolism and longevity

    by Rahagir Salekeen, Hasanul Banna Siam, Dilara Islam Sharif, Michael S. Lustgarten, Morsaline Billah, Kazi Mohammed Didarul Islam

    Recent evidence has prompted the notion of gut‐microbial signatures as an indirect marker of aging and aging‐associated decline in humans. However, the underlying host‐symbiont molecular interactions contributing to these signatures remain poorly understood. In this study, we address this gap using cheminformatic analyses to elucidate potential gut microbial metabolites that may perturb the longevity‐associated NAD+ metabolic network. In silico ADMET, KEGG interaction analysis, molecular docking, molecular dynamics simulation, and molecular mechanics calculation predict a large number of safe and bioavailable microbial metabolites to be direct and/or indirect activators of NAD+‐dependent sirtuin proteins. Our simulation results suggest dihydropteroate, phenylpyruvic acid, indole‐3‐propionic acid, phenyllactic acid, all‐trans‐retinoic acid, and multiple deoxy‐, methyl‐, and cyclic nucleotides from intestinal microbiota as the best‐performing regulators of NAD+ metabolism. Retracing these molecules to their source microorganisms also suggest commensalEscherichia, Bacteroides, Bifidobacteria, andLactobacillito be associated with the highest number of pro‐longevity metabolites. These findings from our early‐stage study, therefore, provide an informatics‐based context for previous evidence in the area and grant novel insights for future clinical investigation intersecting anti‐aging drug discovery, probiotics, and gut microbial signatures.


  • Open Access

    Investigation of the Diet-Gut-Muscle Axis in the Osteoporotic Fractures in Men Study

    by K. Barger, L. Langsetmo, E. S. Orwoll, Michael S. Lustgarten


  • Open Access

    The Kidney–Gut–Muscle Axis in End-Stage Renal Disease is Similarly Represented in Older Adults

    by Michael S. Lustgarten

    Decreased renal function, elevated circulating levels of urea, intestinal levels of urea-degrading bacteria, and gut-derived uremic metabolites are present in end-stage renal disease (ESRD), a cohort that has reduced muscle mass and physical function, and poor muscle composition. This phenotype, defined as the kidney–gut–muscle axis, is similarly represented in older adults that do not have ESRD. The purpose of this short communication is to illuminate these findings, and to propose a strategy that can positively impact the kidney–gut–muscle axis. For example, dietary fiber is fermented by intestinal bacteria, thereby producing the short-chain fatty acids (SCFAs) acetate, propionate, and butyrate, which affect each component of the kidney–gut–muscle axis. Accordingly, a high-fiber diet may be an important approach for improving the kidney–gut–muscle axis in ESRD and in older adults that do not have ESRD.


  • Open Access

    The Role of the Gut Microbiome on Skeletal Muscle Mass and Physical Function: 2019 Update

    by Michael S. Lustgarten

    Within the past year, several studies have reported a positive role for the gut microbiome on the maintenance of skeletal muscle mass, evidence that contrasts previous reports of a negative role for the gut microbiome on the maintenance of whole body lean mass. The purpose of this mini-review is to clarify these seemingly discordant findings, and to review recently published studies that further elucidate the gut-muscle axis.


  • Muscle strength is increased in mice that are colonized with microbiota from high-functioning older adults

    by Roger A. Fielding, Andrew R. Reeves, Ravi Jasuja, Christine Liu, Brittany B. Barrett, Michael S. Lustgarten


  • Open Access

    Impact of Gut Dysbiosis on Neurohormonal Pathways in Chronic Kidney Disease

    by Nima H. Jazani, Javad Savoj, Michael Lustgarten, Wei Ling Lau, Nosratola D. Vaziri

    Chronic kidney disease (CKD) is a worldwide major health problem. Traditional risk factors for CKD are hypertension, obesity, and diabetes mellitus. Recent studies have identified gut dysbiosis as a novel risk factor for the progression CKD and its complications. Dysbiosis can worsen systemic inflammation, which plays an important role in the progression of CKD and its complications such as cardiovascular diseases. In this review, we discuss the beneficial effects of the normal gut microbiota, and then elaborate on how alterations in the biochemical environment of the gastrointestinal tract in CKD can affect gut microbiota. External factors such as dietary restrictions, medications, and dialysis further promote dysbiosis. We discuss the impact of an altered gut microbiota on neuroendocrine pathways such as the hypothalamus–pituitary–adrenal axis, the production of neurotransmitters and neuroactive compounds, tryptophan metabolism, and the cholinergic anti-inflammatory pathway. Finally, therapeutic strategies including diet modification, intestinal alpha-glucosidase inhibitors, prebiotics, probiotics and synbiotics are reviewed.